



Spanish Securities Market Commission
For the attention of: The Manager, Markets Division
C/ Edison núm. 4
28006 Madrid

Pursuant to Article 17 of Regulation (EU) n° 596/2014 on market abuse and Article 228 of the consolidated text of the Spanish Securities Market Act, approved by Royal Legislative Decree 4/2015, of 23 October, we hereby make the following **REGULATORY ANNOUNCEMENT**:

“Pharma Mar, S.A. announces that the Independent Data Monitoring Committee (IDMC) has recommended that the Phase III (ATLANTIS) trial currently under way with Zepsyre® (lurbinectedin, PM1183) in combination with doxorubicin in relapsed small-cell lung cancer patients should continue without any changes. In this regards please find attached press release that Pharma Mar, S.A. will distribute to the media today.”

In Madrid, on 26 October 2018

Pharma Mar S.A.
Avda. de los Reyes, 1
P.I. La Mina
28770 Colmenar Viejo
(Madrid) Spain
www.pharmamar.com



Zepsyre® receives positive recommendation of the IDMC to continue with the Phase III trial in small-cell lung cancer (ATLANTIS)

Madrid, 26 of October 2018.- PharmaMar (MSE:PHM) has announced today that the Phase III ATLANTIS trial has received from the Independent Data Monitoring Committee (IDMC) its recommendation that the trial, currently under way with Zepsyre® (lurbinectedin, PM1183) in combination with doxorubicin in relapsed small-cell lung cancer patients should continue without any changes. This is the fourth IDMC safety data review that has been passed.

The IDMC's recommendation came after having reached the targeted number of 600 patients recruited.

The ATLANTIS trial compares Lurbinectedin plus doxorubicin to physician's choice of either Topotecan or CAV (cyclophosphamide, adriamycin, vincristine) in a 1 to 1 randomization. The primary endpoint is overall survival, and based on the expected number of events, the results are expected around the end of 2019. The trial is 90% powered to deliver a hazard ratio of 0.75.

Legal warning

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

About PharmaMar

Headquartered in Madrid, PharmaMar is a biopharmaceutical company, focused on oncology and committed to research and development which takes its inspiration from the sea to discover molecules with antitumor activity. It is a company that seeks innovative products to provide healthcare professionals with new tools to treat cancer. Its commitment to patients and to research has made it one of the world leaders in the discovery of antitumor drugs of marine origin.

PharmaMar has a pipeline of drug candidates and a robust R&D oncology program. It develops and commercializes Yondelis® in Europe and has other clinical-stage programs under development for several ty-pes of solid cancers: lurbinectedin (PM1183), PM184 and PM14. With subsidiaries in Germany, Italy, France, Switzerland, Belgium, Austria and the United States. PharmaMar wholly owns other companies: GENOMICA, a molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications

of gene silencing (RNAi); and a chemical enterprise, Zelnova Zeltia. To learn more about PharmaMar, please visit us at www.pharmamar.com

About lurbinectedin

Lurbinectedin (PM1183) is a compound under clinical investigation. It is an inhibitor of RNA polymerase II. This enzyme is essential for the transcription process that is over-activated in tumors with transcription addiction.

Media Contact:

Alfonso Ortín – Communications Director aortin@pharmamar.com Mobile: +34 609493127
Miguel Martínez-Cava – Digital Communication Manager mmartinez-cava@pharmamar.com Mobile: +34 606597464
Phone: +34 918466000



Investor Relations:

Phone: +34 914444500

Or please visit our website at www.pharmamar.com